Literature DB >> 32241421

One-pot preparation of hyaluronic acid-coated iron oxide nanoparticles for magnetic hyperthermia therapy and targeting CD44-overexpressing cancer cells.

Meysam Soleymani1, Mohammad Velashjerdi2, Zhila Shaterabadi3, Aboulfazl Barati4.   

Abstract

In the present study, a facile one-pot hydrothermal method is introduced for preparation of hyaluronic acid-coated Fe3O4 nanoparticles (Fe3O4@HA NPs) for theranostic applications. In the proposed method, hyaluronic acid acts simultaneously as a biocompatible coating layer and as a targeting ligand for CD44 receptor overexpressed on the surface of breast cancer cells. The obtained product with narrow hydrodynamic size distribution exhibited a high colloidal stability at physiological pH for more than three months. Cytotoxicity measurements indicated a negligible toxicity of the prepared sample against L929 normal cells. Preferential targeting of Fe3O4@HA NPs to CD44-overexpressing cancer cells was studied by comparing the uptake of the prepared nanoparticles by MDA-MB-231 cancer cells (positive CD44 expression) and L929 normal cells (negative CD44 expression). Uptake of the Fe3O4@HA NPs by MDA-MB-231 cells was found to be 4-fold higher than the normal cells. Also, the in vitro analysis showed that, the uptake of Fe3O4@HA NPs by MDA-MB-231 breast cancer cells is significantly enhanced as compared to non-targeted dextran-coated Fe3O4 NPs. Moreover, the heat generation capability of the Fe3O4@HA NPs for magnetic hyperthermia application was studied by exposing the prepared nanoparticles to different safe alternating magnetic fields (f = 120 kHz, H = 8, 10, and 12 kA/m). The intrinsic loss power obtained for Fe3O4@HA NPs was about 3.5 nHm2/kg, which is about 25-fold larger than that of obtained for commercial available Fe3O4 nanoparticles for biomedical applications. Good colloidal stability, biocompatibility, high heating efficacy, and targeting specificity to CD44 receptor-overexpressing cancer cells could make the Fe3O4@HA NPs as a promising multifunctional platform for diagnosis and therapeutic applications.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Active targeting; CD44 receptor; Fe(3)O(4) nanoparticles; Hyaluronic acid; Hyaluronic acid coated iron oxide; Magnetic hyperthermia

Year:  2020        PMID: 32241421     DOI: 10.1016/j.carbpol.2020.116130

Source DB:  PubMed          Journal:  Carbohydr Polym        ISSN: 0144-8617            Impact factor:   9.381


  6 in total

Review 1.  Advanced Polymeric Nanoagents for Oral Cancer Theranostics: A Mini Review.

Authors:  Guan-Meng Zhang; Shao-Chen Nie; Zhao-Yuan Xu; Ya-Ru Fan; Mai-Ning Jiao; He-Jing Miao; Su-Xia Liang; Ying-Bin Yan
Journal:  Front Chem       Date:  2022-06-14       Impact factor: 5.545

Review 2.  External and Internal Stimuli-Responsive Metallic Nanotherapeutics for Enhanced Anticancer Therapy.

Authors:  Adityanarayan Mohapatra; Saji Uthaman; In-Kyu Park
Journal:  Front Mol Biosci       Date:  2021-01-11

Review 3.  Designing and Immunomodulating Multiresponsive Nanomaterial for Cancer Theranostics.

Authors:  Amreen Khan; Faith Dias; Suditi Neekhra; Barkha Singh; Rohit Srivastava
Journal:  Front Chem       Date:  2021-01-29       Impact factor: 5.221

4.  Effect of different molecular coatings on the heating properties of maghemite nanoparticles.

Authors:  Marco Sanna Angotzi; Valentina Mameli; Shankar Khanal; Miroslav Veverka; Jana Vejpravova; Carla Cannas
Journal:  Nanoscale Adv       Date:  2021-11-08

Review 5.  Immune-regulating camouflaged nanoplatforms: A promising strategy to improve cancer nano-immunotherapy.

Authors:  Biao-Qi Chen; Yi Zhao; Yang Zhang; Yu-Jing Pan; Hong-Ying Xia; Ranjith Kumar Kankala; Shi-Bin Wang; Gang Liu; Ai-Zheng Chen
Journal:  Bioact Mater       Date:  2022-08-10

6.  Glucose-coated superparamagnetic iron oxide nanoparticles prepared by metal vapor synthesis can target GLUT1 overexpressing tumors: In vitro tests and in vivo preliminary assessment.

Authors:  Daniele Barbaro; Lorenzo Di Bari; Valentina Gandin; Cristina Marzano; Andrea Ciaramella; Michele Malventi; Claudio Evangelisti
Journal:  PLoS One       Date:  2022-06-15       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.